Retatrutide: Trials and FDA Status
Retatrutide is a glp-1/gip/glucagon triple agonist. This page tracks its trials, sponsor and FDA status, with a dated source for each milestone.
Where it stands
- US status
- Investigational · phase 3 (TRIUMPH)
- Phase
- Phase 3
- Sponsor
- Eli Lilly
- Expected FDA decision
- Sponsor statement
- Lilly states it plans to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027 (a submission plan, not an FDA decision date).
- Trial IDs (NCT)
- NCT04881760, NCT04867785, NCT05929066, NCT05929079, NCT05882045, NCT05931367
Reported results
- 2026TRIUMPH-1 phase 3 (NEJM 2026): mean weight change at 80 weeks vs placebo“The mean percent change in body weight in the retatrutide groups was -17.6% (4-mg dose), -23.7% (9-mg dose), and -25.0% (12-mg dose) versus -3.9% in the placebo group”pubmed.ncbi.nlm.nih.gov
- 2023Phase 2 (NEJM 2023): weight change at 48 weeks“At 48 weeks, the least-squares mean percentage change in the retatrutide groups was -8.7% in the 1-mg group, -17.1% in the combined 4-mg group, -22.8% in the combined 8-mg group, and -24.2% in the 12-mg group, as compared with -2.1% in the placebo group.”pubmed.ncbi.nlm.nih.gov
- Weight change, 12 mg at 80 weeks (TRIUMPH-1 phase 3, NEJM 2026; treatment-regimen estimand)[2]−25.0%
- Weight change, 9 mg at 80 weeks (TRIUMPH-1)[2]−23.7%
- Weight change, 4 mg at 80 weeks (TRIUMPH-1)[2]−17.6%
- Weight change, placebo at 80 weeks (TRIUMPH-1)[2]−3.9%
- Weight change, 12 mg at 80 weeks (TRIUMPH-1 efficacy estimand, company-reported)[1]−28.3%
- Weight change, 12 mg at 48 weeks (phase 2, NEJM 2023; placebo −2.1%)[3]−24.2%
Company-reported figures are labelled as such. Results in a trial population may not match results elsewhere.
Milestones
Expected decision: Lilly states it plans to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027 (a submission plan, not an FDA decision date). Eli Lilly (press release)
- Retatrutide phase 3 TRIUMPH-1 results publishedTrial
- FDA warning letters to five research-peptide sellersEnforcement
- Eli Lilly sues six retatrutide sellersOther
- Lilly reports positive data from three additional Phase 3 retatrutide obesity trials and a complete clinical package
- NCT05929079 (TRIUMPH-2; Phase 3): primary completion
- NCT05882045 (TRIUMPH-3; Phase 3): primary completion
- NCT05929066 (TRIUMPH-1; Phase 3): primary completion
- Seven FDA warning letters to online sellers of GLP-1 productsEnforcement
- Published in The New England journal of medicine (2026): Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.
- Published in Lancet (London, England) (2026): Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.
- NCT05931367 (TRIUMPH-4; Phase 3): primary completion
- NCT05931367 (TRIUMPH-4; Phase 3): study start
- NCT05929079 (TRIUMPH-2; Phase 3): study start
- NCT05929066 (TRIUMPH-1; Phase 3): study start
- NCT05931367 (TRIUMPH-4; Phase 3): first posted on ClinicalTrials.gov
- NCT05929066 (TRIUMPH-1; Phase 3): first posted on ClinicalTrials.gov
- NCT05929079 (TRIUMPH-2; Phase 3): first posted on ClinicalTrials.gov
- NCT05882045 (TRIUMPH-3; Phase 3): first posted on ClinicalTrials.gov
- NCT05882045 (TRIUMPH-3; Phase 3): study start
- Published in The New England journal of medicine (2023): Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
- NCT04867785 (A Study of LY3437943 in Participants With Type 2 Diabetes; Phase 2): primary completion
- NCT04881760 (A Study of LY3437943 in Participants Who Have Obesity or Are Overweight; Phase 2): primary completion
- NCT04881760 (A Study of LY3437943 in Participants Who Have Obesity or Are Overweight; Phase 2): study start
- NCT04867785 (A Study of LY3437943 in Participants With Type 2 Diabetes; Phase 2): study start
- NCT04881760 (A Study of LY3437943 in Participants Who Have Obesity or Are Overweight; Phase 2): first posted on ClinicalTrials.gov
- NCT04867785 (A Study of LY3437943 in Participants With Type 2 Diabetes; Phase 2): first posted on ClinicalTrials.gov
What the retatrutide registry entries specify
NCT05929066 (TRIUMPH-1) calls itself a randomised, double-blind, placebo-controlled study in its official title.[6]
TRIUMPH-1: Eli Lilly and Company registers 2335 participants (actual enrolment).[6]
TRIUMPH-1 is completed: start 2023-07-10, actual primary completion 2026-04-06.[6]
The TRIUMPH-1 registry lists an extension in which participants receive retatrutide for an additional 24 weeks after the 80-week placebo-controlled period.[6]
The knee osteoarthritis trial: Eli Lilly and Company registers 445 participants (actual enrolment).[9]
The knee osteoarthritis trial is completed: start 2023-08-01, actual primary completion 2025-11-14.[9]
The earlier phase 2 obesity trial (NCT04881760) used the code LY3437943, and its top arm is described as stepping through 2 mg, 4 mg, 8 mg and then 12 mg once weekly.[4]
Primary endpoints and trial length
TRIUMPH-1 also carries a sleep apnea endpoint: the registry lists change in apnea-hypopnea index events per hour, in a subset, as a primary outcome.[6]
The knee trial's primary outcomes include the WOMAC pain subscale alongside body weight, so pain is a registered primary endpoint there.[9]
Start to primary completion: TRIUMPH-1 143 weeks; knee trial 119 weeks.
Calculated from NCT05929066 start 2023-07-10, primary completion 2026-04-06, type ACTUAL; NCT05931367 start 2023-08-01, primary completion 2025-11-14, type ACTUAL. Formula: weeks = round((primary completion date - start date) / 7 days); dates with no day are taken as the 15th
Published results so far
Published TRIUMPH-1 weight change was -17.6% at 4 mg, -23.7% at 9 mg and -25.0% at 12 mg, against -3.9% on placebo.[2]
Among TRIUMPH-1 participants with knee osteoarthritis, pain scores changed by -3.2, -3.5 and -3.6 on retatrutide versus -1.9 on placebo (hybrid estimand).[2]
In TRIUMPH-2, in adults with obesity and type 2 diabetes, permanent discontinuation for adverse events or death was 12% at 9 mg and 8% at 12 mg, against 5% on placebo.[14]
In the phase 2 trial the 12 mg group changed by -24.2% at 48 weeks, against -2.1% on placebo.[3]
Retatrutide FDA approval status in 2026
A Drugs@FDA (openFDA) lookup of the active ingredient retatrutide on 2026-10-02 returned no matches, so no retatrutide application is approved.[16]
Lilly's second-quarter earnings release says it plans to submit a Biologics License Application to FDA in the first quarter of 2027; that is a plan, not an FDA decision date.[15]
Lilly's second-quarter earnings release adds that positive data from three more phase 3 retatrutide obesity trials were reported and that the clinical data package is now complete for obesity, sleep apnea and knee osteoarthritis pain registrations.[15]
Under federal law, FDA states, retatrutide cannot be used in compounding.[17]
FDA has also warned telehealth companies that marketed retatrutide directly to consumers.[17]
PeptideDeck, our sister site, keeps a separate guide on where to buy retatrutide.
Common questions
Is retatrutide FDA approved?
No. FDA describes retatrutide as not part of any approved drug and not found safe and effective for any condition.[17]
What is the retatrutide release date?
No release date exists. Lilly's stated next step is a BLA submission planned for the first quarter of 2027.[15]
What were the retatrutide results?
The 12 mg arm of the phase 3 TRIUMPH-1 trial lost 25.0% of body weight on average versus 3.9% on placebo, as reported in the published abstract.[2]
When will retatrutide be available?
Retatrutide is not available by prescription because nothing is approved; the one dated step in these sources is Lilly's planned FDA submission, and none of them gives an FDA decision date or a waitlist.[15]
Is retatrutide approved by the EMA?
Searching the EMA medicines export generated 02/10/2026 (2746 rows) for retatrutide gives 0 matching rows, so it lists no centrally authorised retatrutide medicine; nationally authorised medicines are not in that list.[18]
What company is developing retatrutide (LY3437943)?
Eli Lilly and Company is the sponsor of the phase 2 obesity registry entry, which uses the code LY3437943 in its title.[4]
Sources
- 1Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (21 May 2026)Eli Lilly and Company (press release) · 2026investor.lilly.comAccessed 2 Oct 2026
- 2Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1; Jastreboff AM et al.)New England Journal of Medicine · 2026PMID 42814954Accessed 2 Oct 2026
- 3Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial (Jastreboff AM et al.)New England Journal of Medicine · 2023PMID 37366315Accessed 2 Oct 2026
- 4A Study of LY3437943 in Participants Who Have Obesity or Are Overweight (NCT04881760)ClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
- 5A Study of LY3437943 in Participants With Type 2 Diabetes (NCT04867785)ClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
- 6TRIUMPH-1: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (NCT05929066)ClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
- 7TRIUMPH-2: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (NCT05929079)ClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
- 8TRIUMPH-3: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (NCT05882045)ClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
- 9TRIUMPH-4: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee (NCT05931367)ClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
- 10Retatrutide phase 3 TRIUMPH-1 results publishedNEJM (PubMed 42814954) · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 12Eli Lilly sues six retatrutide sellersEli Lilly (press release) · 2026investor.lilly.comAccessed 2 Oct 2026
- 13Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 14Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2026PMID 42810372Accessed 2 Oct 2026
- 15Lilly reports positive data from three additional Phase 3 retatrutide obesity trials and a complete clinical packageEli Lilly (press release) · 2026sec.govAccessed 2 Oct 2026
- 16Drugs@FDA (openFDA) search: active ingredient "retatrutide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 17Official web pageOfficial web page · web page
- 18ema.europa.eu pageEuropean Medicines Agency · 2026ema.europa.euAccessed 2 Oct 2026
Found an error? Report a correction.